Since the heterogeneity among those studies for HER-2 expression was insignificant (I2 = 0 %), a fixed-effect model was used to calculate the pooled HR with corresponding 95 % CI of OS in CRC patients. The gene discussed is ERBB2; the disease is colorectal carcinoma.